Journal of Diabetes and Metabolic Disorders最新文献

{"title":"Osteoporosis and fracture risk after cholecystectomy: A Systematic review and meta-analysis.","authors":"Amirhossein Ghaseminejad-Raeini, Amirhossein Shirinezhad, Alireza Azarboo, Seyed Hossein Hosseini-Asl, Leila Zeinab Khan, Fatemeh Mousavi Eshlaghi, Kasra Pirahesh","doi":"10.1007/s40200-026-01921-8","DOIUrl":"10.1007/s40200-026-01921-8","url":null,"abstract":"<p><strong>Background: </strong>Cholecystectomy, a common surgical procedure for treating gallbladder diseases, has been associated with metabolic and endocrine changes that may impact bone health. This systematic review and meta-analysis aim to evaluate the risk of osteoporosis and fractures in patients undergoing cholecystectomy.</p><p><strong>Methods: </strong>A systematic literature search was conducted across major databases to identify relevant studies. Inclusion criteria comprised studies investigating osteoporosis and fracture outcomes in patients who underwent cholecystectomy. The Joanna Briggs Institute (JBI) Risk of Bias Tool was employed to evaluate the methodological quality of the included studies. Meta-analysis was performed using hazard ratios where available.</p><p><strong>Results: </strong>We included 8 studies, comprising 624,290 cholecystectomy patients and 2,006,246 controls. The meta-analysis revealed a 1.08-fold increase (95% CI: 1.05-1.11) in fracture risk for post-cholecystectomy patients compared to controls. In the descriptive synthesis of osteoporosis incidence, some studies showed an association with cholecystectomy. On the other hand, some studies reported the aforementioned outcomes to show no difference in cases and controls. Several studies reported that bone mineral density (BMD) status was worse in cholecystectomy cases, whereas a few suggested to be the same between groups.</p><p><strong>Conclusions: </strong>Although our meta-analysis shows a modest increase in fracture risk among post-cholecystectomy patients, it remains unclear whether cholecystectomy is associated with higher osteoporosis risk or poorer BMD, as studies yielded conflicting results. These discrepancies highlight the need for further prospective studies to clarify the relationship between cholecystectomy and bone health outcomes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-026-01921-8.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"121"},"PeriodicalIF":1.6,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis.","authors":"Louie Kamel-Abusalha, Ahmed M Afifi, Abdallatif Dawoud, Zumair Hayath, Muhammad Fouad Bouso, Andre Aguillon, Ragheb Assaly","doi":"10.1007/s40200-026-01929-0","DOIUrl":"10.1007/s40200-026-01929-0","url":null,"abstract":"<p><p>Our study sought to evaluate the association between Glucagon-like peptide-1 receptor agonist use and the development of hypersomnolence at 1 and 5-year timepoints. A retrospective cohort study was done using TriNetX's research network. Patients aged 18-50 with type-2 diabetes mellitus or obesity who underwent polysomnography were included. Patients were excluded if they had any prior use of antidepressants. Patients who used Glucagon-like peptide-1 receptor agonists were 1:1 propensity matched to patients without Glucagon-like peptide-1 receptor agonist exposure. The primary outcome was new onset hypersomnolence with secondary outcomes including parasomnia, narcolepsy/cataplexy, disturbed sleep, restless legs syndrome, iron deficiency, and Parkinsonism. Hazard ratios and risk ratios were calculated at 1- and 5-years. Kaplan-Meier analyses and log-rank tests were performed for time to event comparisons. After matching, there were two equal cohorts of 118,993 patients. The Glucagon-like peptide-1 receptor agonist cohort was associated with increased hypersomnolence at 1-year (HR 1.21, 95% CI 1.10-1.32; <i>p</i> < 0.001) and 5-years (HR 1.23, 95% CI 1.14-1.32; <i>p</i> < 0.001). The absolute risk increase was approximately 0.4% at 1 year and 0.7% at 5 years. Iron deficiency was significantly increased at 5-years (HR 1.11, 95% CI 1.06-1.16; <i>p</i> < 0.001). A decreased hazard of Parkinsonism was observed at 5-years (HR 0.26, 95% CI 0.08-0.80; <i>p</i> = 0.012), although event counts were low. Time to event analyses did not demonstrate statistically significant associations for parasomnia, disturbed sleep, restless legs syndrome, or narcolepsy/cataplexy. These findings highlight the need for further studies to evaluate the effects of Glucagon-like peptide-1 receptor agonists on sleep regulation and the neurophysiological consequences of these agents.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-026-01929-0.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"117"},"PeriodicalIF":2.1,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13000040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of cocoa products in individuals with metabolic syndrome and related diseases: a systematic review and meta-analysis.","authors":"Amanda Gomes Chagas, Bruno Giusti Camilotti, Gabriela Nascimento Gonçalves, Leandro Roberto de Macedo, Maísa Silva","doi":"10.1007/s40200-026-01914-7","DOIUrl":"10.1007/s40200-026-01914-7","url":null,"abstract":"<p><p>Cocoa supplementation has been shown to improve parameters related to metabolic syndrome, although results have been contradictory. We conducted a systematic review and meta-analysis to examine the effect of cocoa products on lipid and glycemic profiles, blood pressure levels, and anthropometric measurements in individuals with metabolic syndrome and related diseases. A search of PubMed, Web of Science, Embase, and Scopus was performed to identify randomized clinical trials (RCTs). To compare the effects of the cocoa product with placebo, mean differences with 95% confidence intervals (CIs) were pooled using a random-effects model. Subgroup analyses and meta-regression were performed to identify the source of heterogeneity, and study quality assessment was conducted using the GRADE approach. A total of 13 RCTs, including 16 arms, that investigated the effects of cocoa on parameters related to metabolic syndrome were included. The meta-analysis showed a significant effect of cocoa supplementation on triacylglycerol levels (-0.21 mmol/L, 95% CI: -0.40, -0.02; <i>p</i> = 0.0333), and subgroup analysis suggested that cholesterol levels were reduced with cocoa supplementation in patients with dyslipidemia and diabetes. Furthermore, the meta-regression analysis suggested a decrease in glycemic and lipid profiles, as well as anthropometric parameters, in studies with longer durations of cocoa supplementation. Our study suggests that cocoa intake has limited evidence of benefit, mainly for triglycerides, furthermore, effects and that the duration, type, and clinical status of patients were important determinants for favorable effects on biomarkers related to metabolic syndrome.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-026-01914-7.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"116"},"PeriodicalIF":2.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12996486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The psychological burden of diabetes: common mental health disorders, their impact on disease outcomes and strategies for intervention.","authors":"Javed Latoo, Yasser Saeed Khan, Armaan Latoo, Majid Alabdulla, Farida Jan, Nasseer Masoodi, Daljit Sura, Shariful Islam, Ovais Wadoo","doi":"10.1007/s40200-026-01915-6","DOIUrl":"10.1007/s40200-026-01915-6","url":null,"abstract":"<p><p>Diabetes mellitus is associated with a high burden of mental health issues, including both formal psychiatric disorders, such as depression and anxiety, and diabetes-specific psychological challenges like diabetes-related distress, psychological insulin resistance, and fear of hypoglycemia. These mental health difficulties significantly impair self-management, treatment adherence, and quality of life, increasing the risk of complications and mortality. The paper reviews the bidirectional relationship between diabetes and mental disorders, driven by biological and behavioural mechanisms. It highlights the high prevalence of depression, anxiety, cognitive impairment, and eating disorders among people with diabetes. The consequences of untreated mental health conditions include poor glycemic control, greater healthcare costs, increased hospitalization, and lower health-related quality of life. The review presents a range of evidence-based management strategies, including early screening, psychological and pharmacological interventions, lifestyle changes, and integrated collaborative care models. Particular emphasis is placed on the role of physicians and endocrinologists in recognizing and managing psychological difficulties. The paper also discusses challenges in low-resource settings and underscores the need for culturally adapted accessible interventions. It argues for a paradigm shift towards integrated, person-centred care models that address both physical and mental health needs in diabetes, offering practical recommendations for clinicians and policymakers.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"105"},"PeriodicalIF":2.1,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12965932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous glucose monitoring in paediatric residents with normal glucose metabolism: correlations to 24-hour duty schedule.","authors":"Georgia Sotiriou, Anastasia Proimou, Paraskevi Panagopoulou, Zoi Tsimtsiou, Athanasios Christoforidis","doi":"10.1007/s40200-026-01871-1","DOIUrl":"10.1007/s40200-026-01871-1","url":null,"abstract":"<p><strong>Purpose: </strong>Glucose values in healthy humans are influenced by dietary habits, stress, hormonal signaling and lack of adequate sleep. Our aim was to quantify glucose fluctuations in healthy paediatric residents with the use of commercial continuous glucose monitoring systems(CGMS).</p><p><strong>Methods: </strong>Eligibility criteria were: i)participation in the full on-call duty schedule, ii)age: 25-40 years, iii)normal body mass index (BMI) iv)absence of chronic disease or treatment affecting glucose metabolism and v)signed informed consent.</p><p><strong>Results: </strong>Fifteen sensors were placed in 13 residents (8 females). They were monitored for 35 days of 24-hour duty shift in the Emergency Department (ED), 35 days after a 24-hour ED shift and 114 days away from 24-hour ED shift (regular 8-hour shift days). Time in normoglycemia (70-140 mg/dl) was lower and time in higher glucose ranges (141-180 mg/dl and 181-250 mg/dl) was higher during ED duty shifts. Most participants showed a significant increase in mean glucose during 24-hour ED duty shifts (97.67 ± 10.84 mg/dl) compared to days after ED duty (94.68 ± 10.16 mg/dl, <i>p</i> = 0.002) and regular working days (97.85 ± 10.08 mg/dl, <i>p</i> < 0.001). Glucose variability, assessed by coefficient of variation, was also higher during ED duty days (15.78) than on days after ED duty (13.85) and regular days (12.91). Night-time glucose (00.00-06.00) was similarly elevated during ED duty shifts (98.85 ± 11.85 mg/dl) compared to nights after ED duty (90.59 ± 10.99 mg/dl, <i>p</i> = 0.002) and nights on regular working days (90.72 ± 10.06 mg/dl, <i>p</i> = 0.003).</p><p><strong>Conclusions: </strong>24-hour ED duty shifts significantly affect glucose values of Paediatric residents. Further studies are warranted to confirm and further investigate these preliminary data.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"97"},"PeriodicalIF":2.1,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerating care, capacity and equity in automated insulin delivery systems for New Zealanders with type 1 diabetes: the ACCESS-AID study protocol.","authors":"Jennifer T Gale, Alisa Boucsein, Jonathan Williman, Claire Lever, Hamish Crocket, Ofa Dewes, Shelley Rose, Helen Snell, Chunhuan Lao, Martin de Bock, Craig Jefferies, Rosemary Hall, Shekar Sehgal, Shirley Jones, Ryan Paul, Benjamin J Wheeler","doi":"10.1007/s40200-026-01864-0","DOIUrl":"10.1007/s40200-026-01864-0","url":null,"abstract":"<p><strong>Purpose: </strong>Automated insulin delivery (AID) systems are the gold standard for managing type 1 diabetes (T1D), yet access remains inequitable due to funding disparities, workforce limitations, bias, and geographic barriers. The ACCESS-AID study aims to implement a new model of care by using a remote 'Hub' to deliver prioritised training and support to those most in need and to improve workforce capacity by working in partnership with New Zealand's National Public Health service.</p><p><strong>Methods: </strong>Eligible participants include all individuals with T1D and eligible people with pancreatogenic/Type 3c diabetes). Enrolment will use a prioritisation score. After informed consent and baseline assessments, participants receive one-day AID training (in-person or remote) by certified, industry provided trainers, followed by 12-weeks of structured support from Hub staff. The primary outcome is implementation effectiveness. Secondary outcomes: clinical and psychosocial impacts, safety, nutrition education effectiveness, and qualitative insights. CGM metrics and HbA1c will be assessed at baseline and 12-weeks, and CGM again at 24-weeks. Hub staff will receive training in AID management, complete self-efficacy assessments, and participate in interviews.</p><p><strong>Conclusion: </strong>This model offers a novel, scalable and equity-focused approach to diabetes technology care, which will enhance outcomes for people with diabetes and inform future service delivery for other long-term conditions.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"96"},"PeriodicalIF":2.1,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147355264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Point prevalence of motor neuropathy in children and adolescents with type 1 diabetes mellitus.","authors":"Joana Helena Bourbon Lopes, Jacinta Fonseca, Fernando Silveira, Cíntia Castro-Correia","doi":"10.1007/s40200-026-01865-z","DOIUrl":"10.1007/s40200-026-01865-z","url":null,"abstract":"<p><strong>Purpose: </strong>Our objective is to conduct a screening for motor neuropathy in children and adolescents with type 1 diabetes to assess its point prevalence and to analyse potential risk factors associated with any positive motor neuropathy diagnosis.</p><p><strong>Methods: </strong>This is a cross-sectional study involving children aged 12 to 18 years who have been diagnosed with diabetes for five or more years and are receiving treatment with an insulin pump. All participants underwent a neurological examination and were questioned about symptoms of neuropathy. A nerve conduction study was conducted to evaluate the median, ulnar, common peroneal, and tibial motor nerves. Sensory nerves were also examined. The F-wave response of the tibial nerve was analysed, and needle electromyography was performed on a proximal and distal muscle of the lower limb.</p><p><strong>Results: </strong>A total of 29 children completed the study (mean age: 15.34 ± 1.56 years; mean duration of diabetes: 11.93 ± 2.84 years; HbA1c levels: 7.50 ± 1.17%). Results were normal, indicating adequate motor nerve integration and excluding the presence of motor neuropathy as well as peripheral neuropathy, even at subclinical level.</p><p><strong>Conclusion: </strong>In our studied population, which receives tight monitoring and support for diabetes management, using nerve conduction studies to detect early subclinical motor neuropathy shows no clear benefit. This finding was consistent even among individuals with poor metabolic control, altered albumin/creatinine ratio, and diabetes duration over 10 years, with no abnormalities observed. We recommend following the latest guidelines provided by the American Diabetes Association (ADA).</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-026-01865-z.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"88"},"PeriodicalIF":2.1,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12946334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolites and proteins may mediate the relationship between diet quality and insulin sensitivity in young adult cohort.","authors":"Elizabeth Costello, Jesse A Goodrich, Brittney O Baumert, Shiwen Li, Shudi Pan, William B Patterson, Douglas I Walker, Sarah Rock, Frank D Gilliland, Michael I Goran, Max T Aung, Sandrah P Eckel, Tanya L Alderete, Zhanghua Chen, David V Conti, Lida Chatzi","doi":"10.1007/s40200-026-01918-3","DOIUrl":"10.1007/s40200-026-01918-3","url":null,"abstract":"<p><strong>Purpose: </strong>Poor diet quality is a known risk factor for type 2 diabetes and related outcomes, including declines in insulin sensitivity. Biological changes that occur in response to diet may explain this relationship.</p><p><strong>Methods: </strong>This study was conducted in a cohort of young adults (the MetaAIR study, <i>n</i> = 77, 52% female, 57% Hispanic). High dimensional mediation analyses (HIMA) were performed to identity potential metabolite, protein, and miRNA mediators of the relationship between the Healthy Eating Index-2015 (HEI) and insulin sensitivity (Matsuda Index) over a four year follow up period. Features identified by HIMA and significant after correction for multiple comparisons (q < 0.05) were assessed using causal mediation analyses. The indirect effects and proportion mediated by each feature were calculated independently.</p><p><strong>Results: </strong>Each point increase in HEI was associated with a 0.051 (95% CI:0.004, 0.098) point increase in Matsuda Index. Four potential mediators were identified using HIMA: three metabolites (5Z,8Z,11Z-eicosatrienoic acid, pipecolic acid, and biotin), and one protein (F9). Each of these features exhibited a positive indirect effect and independently mediated between 35 and 43% of the total effect. No miRNAs were selected as potential mediators.</p><p><strong>Conclusion: </strong>These findings suggest that specific metabolites and proteins may mediate the association between diet and diabetes-related outcomes such as declines in insulin sensitivity, likely through pathways related to inflammation. F9, biotin, pipecolic acid, and 5Z,8Z,11Z-eicosatrienoic acid may be potential targets for monitoring efforts for diet adherence or disease prevention.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-026-01918-3.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"90"},"PeriodicalIF":2.1,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12946319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management.","authors":"Maryam Chaudhry, Said Sif","doi":"10.1007/s40200-025-01831-1","DOIUrl":"10.1007/s40200-025-01831-1","url":null,"abstract":"<p><p>Type II diabetes mellitus (T2DM) is a multidimensional metabolic disorder driven by insulin resistance, chronic inflammation and β-cell dysfunction. Emerging evidence shows that epigenetic mechanisms i.e., DNA methylation, histone acetylation and noncoding RNAs, form a key nexus between genetic predisposition and environmental factors including diet, oxidative stress and obesity. These inheritable yet reversible modifications shape transcriptional control of key genes involved in inflammatory signalling, glucose metabolism and insulin secretion. Altered methylation of PDX1 and GLP-1R genes, overexpression of histone deacetylases, impairment of miRNA expression (e.g., miR-21, miR-146a) and lncRNAs (e.g., MALAT) cumulatively impair insulin sensitivity and β-cell identity. In addition, transgenerational epigenetic inheritance reveals how parental nutrition choices and metabolic status can predispose offspring to metabolic memory of T2DM risk. Emerging evidence highlights the promise of targeting epigenetic modifiers e.g., DNMT, HDAC inhibitors and miRNA-based strategies to reverse the abnormalities and regain normal gene expression and metabolic balance. Complementarily, the Wnt/ β-catenin and GLP-1 signalling pathways are key interfaces of epigenetic modulation of β-cell function. Understanding these mechanisms is a gateway for precision medicine that goes beyond glycaemic control in the direction of disease modification and prevention. Integrating epigenetic profiling into clinical management can redefine patients care therapies covering both molecular and heritable dimensions of T2DM.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"82"},"PeriodicalIF":2.1,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12936327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147325745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycated hemoglobin and dynapenia in community- dwelling older people with and without diabetes: A cross-sectional study.","authors":"André Luiz da Silva, Daniela Braga Lima, Gustavo Andrade Brancaglion, Guilherme Eustáquio Furtado, Ligiana Pires Corona, Tábatta Renata Pereira de Brito","doi":"10.1007/s40200-026-01868-w","DOIUrl":"10.1007/s40200-026-01868-w","url":null,"abstract":"<p><strong>Purpose: </strong>Dynapenia, an age-related loss of muscle strength, is associated with adverse outcomes in older people. Elevated glycated hemoglobin (HbA1c) levels may accelerate muscle decline, especially in individuals with diabetes mellitus. This study aimed to determine whether HbA1c levels are associated with dynapenia in community-dwelling older people, and whether this association differs between those with and without diabetes mellitus.</p><p><strong>Methods: </strong>A population-based cross-sectional study was conducted with a probabilistic sample of 404 community-dwelling older people in southern Brazil. Data collection included home interviews, physical assessments, and laboratory tests. Dynapenia was defined as mean handgrip strength below 26 kg for men and 16 kg for women. HbA1c was measured by high-performance liquid chromatography. Multiple logistic regression was used to assess the association between HbA1c and dynapenia, stratified by diabetes status.</p><p><strong>Results: </strong>The sample was predominantly female (72.0%) and aged 60-69 years (44.3%). The prevalence of diabetes mellitus was 36.4%, and dynapenia was observed in 23.5% of participants. In multivariable logistic regression analysis, higher HbA1c levels were independently associated with dynapenia among older people with diabetes mellitus (adjusted odds ratio = 1.34; 95% confidence interval: 1.05-1.71), regardless of sex, age, body mass index, and physical activity.</p><p><strong>Conclusion: </strong>Glycemic control is crucial to prevent muscle strength decline in older people with diabetes mellitus. Monitoring muscle strength should be part of clinical care to reduce functional impairment and adverse outcomes in this population.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"25 1","pages":"77"},"PeriodicalIF":2.1,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12932786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}